Hematology & Medical Oncology

Quick Links

* (IM Hematology Profile)

Mohamad Hussein

Mohamad Hussein, MD

Director, College of Medicine Internal Medicine

Contact Info

Education

  • MBBCH, Ain Shams University School of Medicine, 1982

Recent Publications

  • Dimopoulos MA Swern AS Li JS Hussein M Weiss L Nagarwala Y Baz R. Response to letter, ''immortal time bias in retrospective analysis. Blood Cancer J.. 5: e327, 2016.
  • Arikian SR Milentijevic D Binder G Gibson CJ Hu XH Nagarwala Y Hussein M Corvino FA Surinach A Usmani SZ. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin.. 31(6) : 1105-15, 2015.
  • Lucas DM Ruppert AS Lozanski G Dewald GW Lozanski A Claus R Plass C Flinn IW Neuberg DS Paietta EM Bennett JM Jelinek DF Gribben JG Hussein MA Appelbaum FR Larson RA Moore DF Jr Tallman MS Byrd JC Grever MR. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. Leuk Lymphoma.. 56(11) : 3031-7., 2015.
  • Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Oliver EF, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. American journal of hematology. 89(1) : 62-7, 2014.
  • Srkalovic G, Hussein MA, Hoering A, Zonder JA, Popplewell LL, Trivedi H, Mazzoni S, Sexton R, Orlowski RZ, Barlogie B. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer medicine. 3(5) : 1275-83, 2014.
  • Lazaryan A, Hussein MA, Reu FJ, Faiman B, Habecker B, Ann Karam M, Reed J, Hamilton K, Waksman J, Bruening K, Srkalovic G, Andresen S, Kalaycio M, Sweetenham JW, Sobecks R, Dean R, Knight R, Zeldis JB, Baz R. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma. American journal of hematology. 89(4) : 349-54, 2014.
  • Remily-Wood ER, Benson K, Baz RC, Chen YA, Hussein M, Hartley-Brown MA, Sprung RW, Perez B, Liu RZ, Yoder SJ, Teer JK, Eschrich SA and Koomen JM. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients Prot. Clin. Appl.. 8: 783–795, 2014.
  • R Vij, PG Richardson, S Jagannath, DS Siegel, RC Baz, G Larkins, M Chen, MH Zaki, MA Hussein, and KC Anderson. Pomalidomide with or without low-dose dexamethasone in patients with relapsed/refractory multiple myeloma: outcomes in patients refractory to lenalidomide and bortezomib J Clin Oncol. 30, 2012.
  • Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF, Abidi MH, Durie BG, Barlogie B. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 116(26) : 5838-41, 2010.
  • Baz R, Patel M, Finley-Oliver E, Lebovic D, Hussein MA, Miller KC, Wood M, Sher T, Lee K, Chanan-Khan AA. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leukemia & lymphoma. 51(6) : 1015-9, 2010.
  • Khoriaty R, Hussein MA, Faiman B, Kelly M, Kalaycio M, Baz R. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions. Clinical lymphoma, myeloma & leukemia. 10(1) : E10-3, 2010.
  • Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ, Barlogie B. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21) : 3510-7, 2009.
  • Choueiri TK, Baz RC, McFadden CM, Khasawneh M, Karam MA, Kelly M, Hussein MA. An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU international. 101(6) : 712-5, 2008.
  • Cheriyath V, Jacobs BS, Hussein MA. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Drugs in R&D. 8(1) : 1-12, 2007.
  • Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA, Terebelo HR, Byrne GE, Levine BL, Boise LH, Lee KP. CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood. 109(11) : 5002-10, 2007.
  • Hussein MA. Multiple myeloma: most common end-organ damage and management. Journal of the National Comprehensive Cancer Network : JNCCN. 5(2) : 170-8, 2007.
  • Hussein MA. Preclinical rationale, mechanisms of action, and clinical activity of anthracyclines in myeloma. Clinical lymphoma & myeloma. 7 Suppl 4: S145-9, 2007.
  • Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC. G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. The Journal of clinical investigation. 117(10) : 3107-17, 2007.
  • Hussein MA. Pharmacotherapy of multiple myeloma. Expert opinion on pharmacotherapy. 7(6) : 767-81, 2006.
  • Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thrombosis and haemostasis. 95(6) : 924-30, 2006.
  • Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 106(4) : 848-58, 2006.
  • Suppiah R, Srkalovic JG, Hussein MA. Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma. Clinical lymphoma & myeloma. 6(4) : 301-5, 2006.
  • Baz R, Hussein MA. Does low-dose aspirin have antineoplastic effects in multiple myeloma? British journal of haematology. 134(3) : 349-50, 2006.
  • Hussein MA, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, Andresen S, Karam MA, Reed J, Faiman B, Kelly M, Walker E. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clinic proceedings. 81(7) : 889-95, 2006.
  • Kalmadi SR, Hussein MA. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta haematologica. 116(1) : 1-7, 2006.
  • Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 108(1) : 403; author reply 404, 2006.
  • Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam MA, Faiman B, Jawde RA, Andresen S, Zeldis J, Hussein MA. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clinic proceedings. 80(12) : 1568-74, 2005.
  • Hussein MA. Lenalidomide: patient management strategies. Seminars in hematology. 42(4 Suppl 4) : S22-5, 2005.
  • Latif T, Hussein MA. Advances in multiple myeloma and spine disease. Clinical lymphoma & myeloma. 6(3) : 228-33, 2005.
  • Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. British journal of haematology. 125(4) : 470-6, 2004.
  • Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 101(3) : 558-66, 2004.
  • Baz R, Alemany C, Green R, Hussein MA. Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer. 101(4) : 790-5, 2004.
  • Hussein MA. Salvage therapy options for myeloma patients. Oncology (Williston Park, N.Y.). 18(10) : 1233-5, 2004.
  • Hussein MA, Anderson KC. Role of liposomal anthracyclines in the treatment of multiple myeloma. Seminars in oncology. 31(6 Suppl 13) : 147-60, 2004.
  • Oancea M, Mani A, Hussein MA, Almasan A. Apoptosis of multiple myeloma. International journal of hematology. 80(3) : 224-31, 2004.
  • Hussein MA. New treatment strategies for multiple myeloma. Seminars in hematology. 41(4 Suppl 7) : 2-8, 2004.
  • Chen Q, Ray S, Hussein MA, Srkalovic G, Almasan A. Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma. Leukemia & lymphoma. 44(7) : 1209-14, 2003.
  • Deitcher SR, Choueiri T, Srkalovic G, Hussein MA. Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. British journal of haematology. 123(5) : 959, 2003.
  • Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. The oncologist. 8 Suppl 3: 39-45, 2003.
  • Agrawal NR, Bukowski RM, Rybicki LA, Kurtzberg J, Cohen LJ, Hussein MA. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer. 98(1) : 94-9, 2003.
  • Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. British journal of haematology. 122(3) : 441-50, 2003.
  • Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 98(8) : 1735-44, 2003.
  • Hussein MA. Trials of arsenic trioxide in multiple myeloma. Cancer control : journal of the Moffitt Cancer Center. 10(5) : 370-4, 2003.
  • Hussein MA. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma. The oncologist. 7 Suppl 1: 20-9, 2002.
  • Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, Bukowski RM. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer. 95(10) : 2160-8, 2002.
  • Srkalovic G, Elson P, Trebisky B, Karam MA, Hussein MA. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Medical oncology (Northwood, London, England). 19(4) : 219-26, 2002.
  • Hussein MA, Juturi JV, Lieberman I. Multiple myeloma: present and future. Current opinion in oncology. 14(1) : 31-5, 2002.
  • Hussein MA. Thalidomide: present and future in multiple myeloma. Expert review of anticancer therapy. 5(1) : 25-31, 2005.